Fundraising FoxAdagio Therapeutics
NASDAQ: IVVDUnicorn · $1.5BWaltham, US · Founded 2020 · Delaware corporation · 15 known investors
Find your way into Adagio Therapeutics
590 people in our graph can introduce you to the Adagio Therapeutics team.
Sign up to see every warm intro you have to Adagio Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adagio Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles. The company markets PEMGARDA, an antibody authorized for pre-exposure COVID-19 prevention in immunocompromised populations, and is advancing VYD2311, a next-generation candidate, through Phase 3 clinical trials.
Founders & leadership
Adagio Therapeutics was founded in 2020 by Tillman U. Gerngross.
Board
Investors · 15
How we know: GV (Google Ventures)'s portfolio page · the S-1 prospectus · funding news · bostonglobe.com · Not right? Tell us
How we know: board seat on SEC Form D · bostonglobe.com · Not right? Tell us
How we know: bostonglobe.com · Not right? Tell us
How we know: the S-1 prospectus · bostonglobe.com · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · bostonglobe.com · Not right? Tell us
How we know: bostonglobe.com · Not right? Tell us
Also in the syndicate · 5
Reported raises · per SEC filings
Form D private placements$489.1M disclosed across 4 of 5 rounds · 1900–2022
▶$23.7MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
- Michael S. WyzgaDirector
- Fred DriscollExecutive Officer
- Tamsin BerryDirector
- Christine LindenboomDirector
- Terry McGuireDirector
- Rebecca DaboraExecutive Officer
- Marc EliaDirector
- Jill AndersenExecutive Officer
- Clive A. MeanwellDirector
- David HeringExecutive Officer, Director
- Ellie HershbergerExecutive Officer
- Tom HeymanDirector
- Offering amount
- $23.7M
- Amount sold
- $23.7M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$335.5MraisedApr 2021 · 36 investors · BiotechnologyRule 506(b)
- Lynn ConnollyExecutive Officer
- Eric KimbleExecutive Officer
- Halley GilbertExecutive Officer
- Terrance McGuireDirector
- Rebecca DaboraExecutive Officer
- Rene RussoDirector
- Howard MayerDirector
- Philip ChaseDirector
- Ellie HershbergerExecutive Officer
- Ajay RoyanDirector
- Tillman U. GerngrossExecutive Officer, Director
- Jane HendersonExecutive Officer
- Laura WalkerExecutive Officer
- Offering amount
- $335.5M
- Amount sold
- $335.5M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$80MraisedNov 2020 · 16 investors · BiotechnologyRule 506(b)
- Halley GilbertExecutive Officer
- Howard MayerDirector
- Marc EliaDirector
- Rene RussoDirector
- Terrance G. McGuireDirector
- Ajay RoyanDirector
- Philip T. ChaseDirector
- Tillman U. GerngrossExecutive Officer, Director
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$49.9MraisedNov 2020 · 24 investors · BiotechnologyRule 506(b)
- Halley GilbertExecutive Officer
- Terrance G. McGuireDirector
- Rene RussoDirector
- Marc EliaDirector
- Philip T. ChaseDirector
- Tillman U. GerngrossExecutive Officer, Director
- Ajay RoyanDirector
- Howard MayerDirector
- Offering amount
- $49.9M
- Amount sold
- $49.9M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Adagio Therapeutics do?
- Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles. The company markets PEMGARDA, an antibody authorized for pre-exposure COVID-19 prevention in immunocompromised populations, and is advancing VYD2311, a next-generation candidate, through Phase 3 clinical trials.
- Who founded Adagio Therapeutics?
- Adagio Therapeutics was founded by Tillman U. Gerngross in 2020.
- Who are Adagio Therapeutics's investors?
- Adagio Therapeutics's investors include GV (Google Ventures), Fidelity Investments, Foresite Capital, Mithril Capital Management, Omega Funds, OrbiMed, Polaris Partners, RA Capital and 2 more.
- How much funding has Adagio Therapeutics raised?
- Adagio Therapeutics has disclosed $489.1M raised across 4 of its 5 known rounds.
- Where is Adagio Therapeutics headquartered?
- Adagio Therapeutics is headquartered in Waltham, US.